

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
03 November 2022 (03.11.2022)



(10) International Publication Number  
**WO 2022/232148 A3**

(51) International Patent Classification:

C07K 14/705 (2006.01) C07K 14/725 (2006.01)  
A61K 39/395 (2006.01) C07K 16/30 (2006.01)  
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/026354

(22) International Filing Date:

26 April 2022 (26.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17/243,096 28 April 2021 (28.04.2021) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 17/243,096 (CON)  
Filed on 28 April 2021 (28.04.2021)

(71) Applicant: **THINK THERAPEUTICS, INC.** [US/US];  
94 Park Avenue, Newton, MA 02458 (US).

(72) Inventors: **GIFFORD, David, Kenneth**; 94 Park Avenue,  
Newton, MA 02458 (US). **CARTER, Brandon**; 350 3rd  
Street, Unit 301, Cambridge, MA 02142 (US).

(74) Agent: **SUPERKO, Colleen** et al.; Wilmer Cutler Pickering  
Hale and Dorr LLP, 60 State Street, Boston, MA 02109  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION




FIG. 1

(57) Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

- (88) Date of publication of the international search report:**  
08 December 2022 (08.12.2022)